202 related articles for article (PubMed ID: 33163928)
1. Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.
Hagimoto H; Kashima S; Doi K; Nakayama S; Sano T; Imai S; Yasufuku T; Muramaki M; Yamada Y
IJU Case Rep; 2020 Nov; 3(6):287-290. PubMed ID: 33163928
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
Front Oncol; 2019; 9():1033. PubMed ID: 31649889
[No Abstract] [Full Text] [Related]
3. [A Case of Multiple Lymph Node Metastases Treated with Nivolumab after an Adrenalectomy for Solitary Adrenal Metastasis of Gastric Cancer after a Gastrectomy].
Nakai M; Ichisawa A; Yamada T; Kimura T; Yonaiyama S; Jin H; Tokura T; Aoki K; Kawashima H; Toyoki Y; Endo M
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2434-2436. PubMed ID: 32156956
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.
Yasuoka S; Hamasaki T; Kuribayashi E; Nagasawa M; Kawaguchi T; Nagashima Y; Kondo Y
Medicine (Baltimore); 2018 Nov; 97(45):e13173. PubMed ID: 30407350
[TBL] [Abstract][Full Text] [Related]
5. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy.
Sejima T; Masago T; Yoshida M; Nishi T; Kawabata Y; Tajima Y; Yumioka T; Honda M; Takenaka A
Int Cancer Conf J; 2021 Oct; 10(4):285-289. PubMed ID: 34567939
[TBL] [Abstract][Full Text] [Related]
6. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
7. Longer Control of Nivolumab in Metastatic Renal Cell Carcinoma Patients with End-Stage Kidney Disease on Dialysis.
Morinaga R; Kawahara T; Miyoshi Y; Yao M; Uemura H
Case Rep Oncol; 2019; 12(2):608-612. PubMed ID: 31543776
[TBL] [Abstract][Full Text] [Related]
8. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
9. [A case of metastatic renal cell carcinoma with no evidence of disease for a long term after a favorable response to molecular-targeted therapy followed by metastasectomy].
Ikehata Y; Takahashi S; Kitamura H; Masumori N; Tsukamoto T
Hinyokika Kiyo; 2013 Jun; 59(6):369-72. PubMed ID: 23827870
[TBL] [Abstract][Full Text] [Related]
10. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V
Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512
[No Abstract] [Full Text] [Related]
11. An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case report.
Kang Y; Armstrong AJ; Hsu DS
Stem Cell Investig; 2022; 9():8. PubMed ID: 36393918
[TBL] [Abstract][Full Text] [Related]
12. Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report.
Shibata Y; Noguchi G; Suzuki T; Osaka K; Umemoto S; Kishida T
Am J Case Rep; 2021 Aug; 22():e932924. PubMed ID: 34358221
[TBL] [Abstract][Full Text] [Related]
13. Prolonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature.
Syrios J; Kechagias G; Tsavaris N
J Med Case Rep; 2012 Sep; 6():303. PubMed ID: 22978809
[TBL] [Abstract][Full Text] [Related]
14. Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab.
Hayashida M; Miura Y; Noda T; Yamanaka T; Tanaka N; Yasuoka S; Oka S; Sakaguchi K; Kinowaki K; Urakami S
IJU Case Rep; 2022 Jul; 5(4):268-272. PubMed ID: 35795114
[TBL] [Abstract][Full Text] [Related]
15. A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab.
Tomioka M; Nakane K; Ozawa K; Iinuma K; Suzui N; Miyazaki T; Koie T
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1356. PubMed ID: 33656804
[TBL] [Abstract][Full Text] [Related]
16. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.
Iribe Y; Furuya M; Shibata Y; Yasui M; Funahashi M; Ota J; Iwashita H; Nagashima Y; Hasumi H; Hayashi N; Makiyama K; Kondo K; Tanaka R; Yao M; Nakaigawa N
Fam Cancer; 2021 Jan; 20(1):75-80. PubMed ID: 32666341
[TBL] [Abstract][Full Text] [Related]
17. Sequential immune-targeted surgical therapy resulted in disease-free survival in a case with advanced renal cell carcinoma.
Nishimura K; Miura N; Sugihara N; Funaki K; Koyama K; Sawada Y; Noda T; Fukumoto T; Miyauchi Y; Kikugawa T; Saika T; Matsumura M; Hashine K; Taniwaki M
BMC Urol; 2021 Sep; 21(1):124. PubMed ID: 34496819
[TBL] [Abstract][Full Text] [Related]
18. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
George G; Schmidt L; Tolat P; Riese M; Kilari D
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
[TBL] [Abstract][Full Text] [Related]
19. Only three cycles of nivolumab showed remarkable durable response and reversible myeloradiculoneuropathy in a patient with metastatic papillary renal cell carcinoma type 2.
Iwasaki K; Shin T; Inoue T; Shibuya T; Hirai K; Ando T; Mimata H
IJU Case Rep; 2021 May; 4(3):139-142. PubMed ID: 33977240
[TBL] [Abstract][Full Text] [Related]
20. Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma.
Nakajima N; Kano T; Oda K; Uchida T; Otaki T; Nagao K; Shimizu Y; Kawakami M; Kim H; Nitta M; Hasegawa M; Kawamura Y; Miyajima A
IJU Case Rep; 2020 Sep; 3(5):215-218. PubMed ID: 32914080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
